EG 427 Announces Compelling Initial Topline Clinical Results with EG110A DNA Medicine in Neurogenic Bladder Patients
October 02, 2025- Over 88% reduction in urinary incontinence episodes achieved in low dose cohort at 12 weeks
- Good tolerability with no systemic side effects
- First DNA medicine to selectively target, at the local level, a specific subtype of sensory neurons
- Fully validates mechanism targeting type-C sensory neurons, opening the door to a broad range of other neurological indications
- Results validate EG 427’s proprietary HERMES nrHSV-1 technology platform
Read the full press release in English or in French
Recent posts
EG 427 Receives U.S. FDA Fast Track Designation for EG110A DNA Medicine in Neurogenic Bladder Patients
EG 427 highlights at ASGCT major advances made with its HERMES platform in neurology using versatile non-replicative herpes vectors
Significant milestone reached for EG 427 with first patient treated with EG110A, first non-replicative herpes vector based genetic medicine for the treatment of neurogenic bladder
